TRGC1 and ovarian carcinoma: In ovarian carcinomas of stage III patients (n=93), polyclonal TCRγ gene rearrangements were observed in 41 out of 93 (44.1%) cases, rarified TCRγ gene rearrangements in 37 out of 93 (39.8%) cases and clonal TCRγ gene rearrangements in 15 out of 93 (16.1%) cases (Figure 4A).